Researchers studied a new way to monitor rectal cancer patients during chemotherapy. They tracked tiny pieces of tumor DNA, called ctDNA, in the blood of 153 patients with locally advanced rectal cancer. The goal was to see if changes in this ctDNA could predict how well the chemotherapy was working on the tumor before surgery.
They found a strong link. Patients whose ctDNA levels did not drop or cleared slowly during treatment were far less likely to have a good response to the chemotherapy. In fact, none of the patients in the highest-risk ctDNA group had a major response. The study showed that a positive ctDNA test, even just once before surgery, was strongly associated with a poor outcome.
It is important to understand what this study does and does not show. This was a research study looking for an association, not a test of whether changing treatment based on ctDNA would help patients. The results are promising, but they need to be confirmed in larger studies designed to see if using this information to personalize treatment actually improves patient survival or quality of life. For now, this is a step toward more personalized cancer care, but not a practice-ready tool.
